ESR1 and breast cancer: The combination of ERα antagonism and ERβ agonism may be especially relevant for the chemoprevention of breast cancer as ER antagonism serves as the basis of current chemo-preventative agents [29,31,32,73,74], while ERβ specific agonists have recently been identified as having potential for the chemoprevention of breast cancer [19,22].